Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026)
Mannkind (MNKD) posted quarterly Non-Current Deffered Revenue of $38.9 million for Q1 2026, down 17.85% year-over-year from $47.4 million in Q1 2025, and down 2.68% quarter-over-quarter from $40.0 million in Q4 2025.
Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Non-Current Deffered Revenue for 10 consecutive years, with $38.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 17.85% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at $38.9 million (down 17.85% YoY), while the FY2025 annual figure was $40.0 million, down 21.86% from the prior year.
- Non-Current Deffered Revenue retreated to $38.9 million in Q1 2026 per MNKD's latest filing, from $40.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $69.8 million in Q4 2023 and bottomed at $1.2 million in Q1 2023.
- Historically, Non-Current Deffered Revenue has averaged $46.8 million across 5 years, with a median of $47.4 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue plunged 95.41% — and 2024, when it jumped 5545.08%.
- Mannkind's Non-Current Deffered Revenue stood at $37.7 million in 2022, then surged by 85.21% to $69.8 million in 2023, then declined by 26.7% to $51.2 million in 2024, then retreated by 21.86% to $40.0 million in 2025, then declined by 2.68% to $38.9 million in 2026.
- Business Quant data shows MNKD's Non-Current Deffered Revenue at $38.9 million in Q1 2026, $40.0 million in Q4 2025, and $48.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 36.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.86 Mn |
| Mar 31, 2026 | 38.91 Mn |
| Dec 31, 2025 | 39.98 Mn |
| Sep 30, 2025 | 48.19 Mn |
| Jun 30, 2025 | 45.47 Mn |
| Mar 31, 2025 | 47.36 Mn |
| Dec 31, 2024 | 51.16 Mn |
| Sep 30, 2024 | 65.15 Mn |
| Jun 30, 2024 | 66.12 Mn |
| Mar 31, 2024 | 67.74 Mn |
| Dec 31, 2023 | 69.79 Mn |
| Sep 30, 2023 | 69.47 Mn |
| Jun 30, 2023 | 60.25 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 37.68 Mn |
| Sep 30, 2022 | 32.00 Mn |
| Jun 30, 2022 | 29.76 Mn |
| Mar 31, 2022 | 26.12 Mn |
| Dec 31, 2021 | 19.54 Mn |
| Sep 30, 2021 | 1.55 Mn |